Opinion of the CVMP on the establishment of maximum residue limits: Sodium salicylate
Opinion of the CVMP on the establishment of maximum residue limits: Sodium salicylate
Opinion of the CVMP on the establishment of maximum residue limits: Sodium salicylate
Summary of opinion: CircoMax,Porcine circovirus vaccine (inactivated recombinant), 05/10/2023, Positive
Summary of opinion: Suiseng Diff/A,clostridioides difficile,clostridium perfringens vaccine, inactivated, 05/10/2023, Positive
Summary of opinion: Porcilis PCV ID,Porcine circovirus vaccine (inactivated), 06/10/2023, Positive
Summary of opinion: CircoMax Myco, 05/10/2023, Positive
Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 3-5 October 2023
EMA Management Board: highlights of October 2023 meeting
Revised CTIS Transparency Rules
ICH guideline E19 on a selective approach to safety data collection in specific late-stage pre-approval or post-approval clinical trials - Scientific guideline
Human medicines European public assessment report (EPAR): Aldurazyme, laronidase, Mucopolysaccharidosis I, Date of authorisation: 09/06/2003, Revision: 24, Status: Authorised